Search bioRxiv⌕ Search

bioRxiv · 10.1101/2022.12.19.521152

Predicting MmpR-based bedaquiline resistance using sequence- and structure-based features

Abstract

Accurate molecular detection of resistance to bedaquiline, a core drug for the treatment of drug resistant tuberculosis, remains challenging. In this study, we investigated whether three sequence- and nine structure-based features describing the impact of Rv0678 variants on the MmpR transcriptional repressor could predict the bedaquiline phenotype of isolates containing Rv0678 variants. Paired genotypic and phenotypic data was used to train a binary random forest classifier. The mean value of the individual features was similar for resistant and susceptible variants (p[≥]0.05). Leave one out cross validation showed predictability of bedaquiline resistance from Rv0678 variants when using a binary classifier with a combination of sequence and structural features (ROC AUC = 0.766; f1 score = 0.746), but the performance was too low for clinically use. Evolutionary conservation of the affected residue was the most important individual feature (mean decrease in impurity = 0.226 {+/-} 0.003) to discriminate bedaquiline resistance from susceptibility. Prediction of bedaquiline resistance was only possible when restricting the data to missense variants, as the selected features could not be applied to Rv0678 insertions and deletions. Additionally, prediction of bedaquiline resistance was only possible when restricting the data to isolates for which the phenotype was determined using Mycobacterial Growth Indicator Tubes, suggesting possible misclassification of the bedaquiline phenotype by other methods. The results of this study suggest that structural features describing Rv0678 missense variants could be used to predict bedaquiline resistance, albeit not yet at the performance level required for clinical practice. Author summaryGuidelines by the World Health Organization indicate that antibiotic resistant tuberculosis should be treated with bedaquiline, a newly discovered antibiotic. However, resistance to bedaquiline has already emerged and is spreading rapidly. More than 500 different variants have been discovered in the bedaquiline resistance genes in Mycobacterium tuberculosis. It is not known which DNA variants specifically drive bedaquiline resistance due to insufficiency of data. Here, we used a machine learning technique to predict whether a variant in the Rv0678 gene confers bedaquiline resistance. To this end, for each variant we defined features that describe the impact of the variant on the MmpR (encoded by the Rv0678 gene) protein structure. These features were then fed into a classification algorithm to predict bedaquiline resistance. We successfully developed a bedaquiline resistance prediction model, although performance was limited. We also found that accurate predictions were only possible when restricting the data to samples that were tested on the MGIT platform, a World Health Organization endorsed method to test for bedaquiline resistance. Our study shows that predicting bedaquiline resistance from protein structural features is feasible. Furthermore, our study provides new insights into phenotypic testing platforms to assess bedaquiline resistance.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Riviere, E., Safarpour, M., Meysman, P., Cuypers, B., Meehan, C., Laukens, K., van Rie, A.. 2022-12-21. Predicting MmpR-based bedaquiline resistance using sequence- and structure-based features. https://doi.org/10.1101/2022.12.19.521152

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

A conserved cysteine-histidine-glutamate metal site identifies DUF501 (Rv1025), an essential uncharacterised protein family of Mycobacterium tuberculosis, as a candidate metalloenzyme and drug target

A substantial fraction of the Mycobacterium tuberculosis proteome remains functionally uncharacterised. Rv1025, a 155-residue protein carrying the domain of unknown function DUF501 (Pfam PF04417), is essential by transposon mutagenesis and vulnerable by CRISPR interference, an attractive but neglected drug target, yet has never been functionally described. The family (4,370 proteins, no Gene Ontology term, no solved structure) is uncharacterised across all organisms and essential in three Actinobacterial genera. A Foldseek search of the AlphaFold model against complete structural databases finds no significant homolog, indicating a novel fold. The operon eno-divIC-Rv1025-ppx2 is conserved across the Actinobacteria phylum, yet AlphaFold-Multimer finds no direct complex between Rv1025 and its neighbour DivIC. Instead, conservation across 8,700 homologous sequences reveals a near-invariant Cys113-His115-Glu59 cluster forming a pocket. Holo AlphaFold3 predictions with Zn, Fe and Mn confidently place a divalent metal on this triad at 2.25-2.47 A; mutating the triad relocates the metal, and an independent backbone-geometry predictor recovers the same site, confirming specificity. The triad is universal across the family: present in all 1,472 near-complete bacterial sequences of the Pfam alignment, with no non-conservative substitution among the 2,228 sequences examined, a defining feature of bacterial DUF501 rather than a mycobacterial peculiarity. We propose that DUF501 is a metal-binding protein and candidate metalloenzyme, the first functional hypothesis for this family, whose conserved, essential metal pocket is a promising drug target. As the predictions build on a conservation-defined site within a fully computational study, they are supportive rather than proof of metal occupancy and warrant experimental validation.

microbiology↗

Mycoplasmal endosymbionts of Trichomonas vaginalis are associated with reduced risk for Chlamydia trachomatis endometrial infection in asymptomatic, coinfected, women.

Trichomonas vaginalis is a protozoan parasite that causes trichomoniasis, the most common curable non-viral sexually transmitted infection, and Chlamydia trachomatis is a bacterial pathogen that can ascend to the upper genital tract and cause pelvic inflammatory disease, infertility, and ectopic pregnancy. T. vaginalis harbors bacterial endosymbionts, including Candidatus Malacoplasma girerdii, an obligate symbiont, and Metamycoplasma hominis, which can live freely or symbiotically. In a 16S rRNA sequencing study of the cervicovaginal microbiome of women at high risk for chlamydial infection, Ca. M. girerdii abundance was one of 13 features predicting lack of chlamydial spread to the endometrium, despite no direct association between T. vaginalis infection and reduced chlamydial ascension. Investigating the relationship between these microorganisms further, we found that T. vaginalis vaginal abundance correlated positively with chlamydial burden in women whose infection was confined to the cervix, while a nonsignificant inverse relationship was seen in women with endometrial spread. Among participants with high chlamydial burden, Ca. M. girerdii was detected exclusively in women without endometrial infection. Both endosymbionts trended toward more frequent detection, and higher abundance, in coinfected women without endometrial spread, while M. hominis abundance correlated strongly with T. vaginalis burden in this group. These findings suggest that mycoplasmal endosymbionts of T. vaginalis, rather than T. vaginalis itself, are microbial factors limiting chlamydial ascension, and point to a three-way interaction between parasite, endosymbiont, and bacterial pathogen that shapes upper genital tract C. trachomatis infection risk.

microbiology↗

Understanding the physiological alterations of Vibrio cholerae upon exposure to L-ascorbic acid

The scourge of cholera remains a major global public health threat. It affects up to 4 million people worldwide and causes tens of thousands of deaths each year. The disease is experiencing a concerning resurgence in many parts of Africa, the Middle East, and Asia. To effectively tackle cholera and circumvent rising antimicrobial resistance, targeted biological and preventive approaches, complementing traditional rehydration, are urgently needed. In this regard, our group has demonstrated the efficacy of L-ascorbic acid in controlling the growth and pathogenesis of Vibrio cholerae in vitro. The present work further provides a mechanistic elucidation of the L-ascorbic acid-mediated physiological changes in V. cholerae and also bolsters such a non-antibiotic approach to control cholera.

microbiology↗